Anocca

Our recent summer Townhall meeting brought our talented and multinational team together to celebrate our progress so far this year and gear up for an important year ahead as we move to becoming a clinical-stage company.    It was a motivational, inspirational, and emotional day that included a moving talk from Niclas Lauren who is battling a terminal cancer diagnosis, reminding us why we are so passionate about what we do.   Our 2024 Townhall reinforced our commitment to advance our innovative TCR-T cell therapies, which unlock new cancer specific targets with transformational potential in solid tumours.   #Biotech #CellTherapy #Cancer #greatplacetowork

We are delighted to welcome Dr. Christiane Hanke-Harloff, PhD to Anocca's Board of Directors! Christiane brings extensive industry experience from the biotechnology, pharmaceutical, and CDMO sectors, that spans current Board membership at InnoCore Pharmaceuticals and Ascenion, as well as having held key executive roles at companies such as Gilead Sciences and Gedeon Richter. Her broad expertise, covering the entire pharmaceutical value chain, will be invaluable as we advance our innovative TCR-T therapies into clinical development for hard-to-treat cancers. 🔗Read our Press Release: https://lnkd.in/exAxc7JA 🔬Learn more about Anocca here: www.anocca.com #Biotech #Pharma #CellTherapy #TCRT #Cancer #Oncology

We are excited to partner with Shinobi Therapeutics and work together to create a new class of innovative off-the-shelf TCR-T-cell therapies for the treatment of solid tumours. Anocca’s unique target discovery technology, to map T-cell targets and build potent TCR libraries, will be combined with Shinobi's proprietary Katana platform to generate immune-evasive, allogeneic, induced pluripotent stem-cell derived T-cell therapies. This collaboration is a significant step towards making transformative T-cell therapies scalable and accessible to patients with hard-to-treat cancers on a global scale. 🔗Read our Press Release: https://lnkd.in/d8vpY7Qr 🔬Learn more about Anocca here: www.anocca.com 🔉Listen below #Biotech #Pharma #CellTherapy #TCRT #Cancer #Oncology

Connect with our CEO Reagan Jarvis and CDO Mark Farmery at BIO International Convention in San Diego, June 3-6. We’re looking forward to meeting other innovators who want to shape the development of T-cell immunotherapies. 🔬Learn more about Anocca here: www.anocca.com #Biotech #Pharma #Onoclogy #CellTherapy #TCRT #BIO2024

🏆 We’re proud to have received the Innovation Champion Award at the EIB AdVenture Debt Summit in Luxembourg, recognising our dedication to bringing transformative TCR-T cell therapies to patients, vital to Europe’s Beating Cancer Plan. Thanks to the European Investment Bank (EIB) for their recognition and support! It was a pleasure to catch up with Y Zhang, Anna Stodolkiewicz, CFA and Anna Lynch. 🔬 Discover our precision approach to TCR-T Cell Therapies: https://lnkd.in/ex4YVHkn 🔗 EIB AdVenture Debt Summit: https://lnkd.in/dxj778px 📷 from L-R: Ambroise Fayolle (VP of the EIB), Jacob Michlewicz (CFO of Anocca), Marc Lemaître (Director General for Research and Innovation European Commission).

👇 Discover how developers and tool providers are tackling cell therapy manufacturing challenges and how Anocca's standardised approach to product manufacture is accelerating TCR-T cell therapy development. Featured in the newly published Genetic Engineering & Biotechnology News article “Cell Therapy Manufacturing: Time to Move Fast”, our CDO Mark Farmery highlights our precision approach to engineering and manufacturing TCR-T cell therapy products with highly specific and potent TCRs against challenging cancer targets and how collaborative innovation is essential for the successful development of this emerging treatment modality. 🔗 Read the article: https://lnkd.in/dFs_RmUm #Biotech #Pharma #Oncology #CellTherapy #TCRT

We’re excited to launch our brand-new website that showcases how we combine our cutting-edge biotechnologies, integrated software ecosystem, and state-of-the-art manufacturing capabilities, to build a pipeline of precision TCR-T cell therapies for the hardest to treat cancers.   🔗 www.anocca.com   #Biotech #Pharma #Oncology #CellTherapy #TCRT Random42 Scientific Communication

Don’t miss our CEO Reagan Jarvis speaking at the TCR-Based Therapies for Solid Tumors in Boston this week! 📅 24 April | 08:00 – 08:30 | Industry Leaders’ Fireside Chat: Unveiling the Future of T-Cell Receptor Therapies: What’s on the Horizon? Reagan will share the latest advancements in TCR therapy together with fellow panellists Peggy Sotiropoulou, CSO at T-knife Therapeutics, and Gavin MacBeath, CEO at TScan Therapeutics. You can learn how our own precision biology platform underpins the creation of extensive libraries of TCR-engineered T cell therapies (TCR-T) to extend target T-cell therapies into treatment of solid tumours. 📅 24 April | 11:40 – 12:00 | Functional Enhancement of TCR from Suboptimal Frameworks Reagan will also delve into enhancing TCR sensitivity, selection methods, and considerations for engineered TCRs for off-target safety profiling. With TCR pipelines taking centre stage, it’s the prime opportunity to connect with us as we prepare to advance our first highly validated TCR-T products into clinical development. 🔗Event info: https://lnkd.in/gF2zkg8 #Biotech #Pharma #Oncology #CellTherapy Hanson Wade Group

Our CTO, Luke Pase is attending the inaugural CRISPR Medicine News Conference from 23-25 April 2024 in Copenhagen! This gathering of the global CRISPR medicine community will spotlight cutting-edge #CRISPR research, covering the most important topics in the therapeutic gene-editing field. Meet Luke there to learn about our advanced TCR-T cell therapy manufacturing technologies and our approaches to gene-editing and talk about partnership in this rapidly evolving space. 🔗Join #CRISPRMED24: https://lnkd.in/eM4N4bct #Biotech #Pharma #Oncology #CellTherapy

We were proud to sponsor another successful Cell & Gene Meeting by Alliance for Regenerative Medicine, this year taking place in historic Rome! Our CEO Reagan Jarvis shared his expert insights during the Science Slam session on "New Frontiers in immuno-oncology For Solid Tumor Treatment”, and then discussed our cutting-edge technology and our journey towards the clinic with our innovative TCR-T products at our company presentation. It was a privilege to connect with industry leaders and peers, explore the latest advancements in cell and gene therapy, and discuss potential collaborations for exciting future endeavours. Our commitment to targeting hard-to-treat solid cancer indications remains steadfast - thank you to all who made #CGMed24 a success! #Biotech #CellandGeneTherapy #Immunotherapy #Cancer #Partnering